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Abstract Umbilical cord blood collected from the
postpartum placenta and cord is a rich source of
hematopoietic stem cells (HSCs) and is an alternative
to bone marrow transplantation. In this review we
wanted to describe the differences (in phenotype,
cytokine production, quantity and quality of cells)
between stem cells from umbilical cord blood, bone
marrow and peripheral blood. HSCs present in cord
blood are more primitive than their counterparts in
bone marrow or peripheral blood, and have several
advantages including high proliferation. With using
proper cytokine combination, HSCs can be effectively
developed into different cell lines. This process is used
in medicine, especially in hematology.
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Hematopoiesis
Blastomeres are the first stem cells in the develop-
ment of the human body. These cells have the ability
to develop into any cell type of the body, so-called
totipotency. In a further development of the
embryo—gastrulation stage, cells lose their properties
of totipotency and begin the speciation process. When
the embryo develops to the stage of gastrula two types
of cells are formed: the throphoblast and embryonic
node. Cells present in the embryonic node are called
pluripotent cells—they have the ability to transform
into all types of cells derived from the ecto-, meso-
and endoderm. After moving to the uterus, these cells
cannot differentiate into germ cells in the placenta
and the surrounding tissue (Stec et al. 2003). In the
further stages, pluripotent cells are transformed into
‘‘tissue stem cells’’, so-called multipotent cells. These
cells are subdivided into two progenies: one parent
stem cell and one daughter cell, which has unipotent
activity. The development process of stem cells is
most readily observed in the hematopoietic system
(Fig. 1) (Jo´siak et al. 2004). All blood cell elements
have their origin in a small population of hematopoi-
etic stem cells, that have the ability to self-replicate,
self-renew and to differentiate into specific cell lines
(Yao et al. 2004).
Fetal hematopoiesis starts at about 2–3 weeks after
fertilization and, initially, takes place in the yolk-sac.
During fetal life, hematopoiesis gradually moves to
the liver, and then after the development of the bones,
at about 5–6 weeks takes place in the bone marrow
(Czajka et al. 1999; Je˛drasiak et al. 1999). A multi-
potential hematopoietic stem cell (HSC) during whole
life divides asynchronously into two daughter cells—
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one HSC and one hematopoietic progenitor cell
(HPC). HPC is the earliest progenitor cell, which,
unlike the HSC, does not have the capacity to self-
renew and is limited to one or more extra lines of
differentiation (Kucia and Drukała 2002) ‘‘where there
is no return,’’ and is removed during programmed cell
death (Dabrowski 1998a; Grskovic et al. 2004). HPC
may give rise to myelocytic precursor colony forming
unit of granulocyte, erythroid, macrophage and
megakaryocyte (CFU-GEMM) or lymphoid precursor
(CFU-Lymph). The targeted cells defined by
some authors as colony forming cells (CFC) originate
from CFU-GEMM or CFU-Lymph (Je˛drasiak et al.
1999).
Colony forming unit of granulocyte, erythroid,
macrophage and megakaryocyte gives rise to cells
such as: colony forming unit of erythroid (CFU-E),
colony forming unit of megakaryocytes (CFU-Meg),
colony forming unit of granulocytes and macrophages
(CFU-GM), colony forming unit of eosinocytes,
colony forming unit of basophiles, colony forming
unit of mastocyte, form which the erythrocytes,
platelets, neutrophils, monocytes, macrophages,
eosinophils, basophils, and the mast cells are gener-
ated, respectively. B cells, NK cells and precursors of
thymocytes are formed from lymphoid precursor
(Dabrowski 1998a).
The morphology of cord blood hematopoietic cells
The morphology of human HSC is similar in appear-
ance to a small cell with a narrow hem cytoplasm, in
which mitochondria and endoplasmic reticulum are
poorly marked (Kopec´-Szle˛zak and Podstawka 2001).
It has the ability to intense proliferation and self-
renewal and the ability to multi-line differentiation
(Belvedere et al. 1999; Brunet de la Grange et al. 2002;
Summers et al. 2001; Thierry et al. 1992). HSC is
maintained in the G0 phase of the cell cycle, does not
exhibit metabolic activity and has almost totally
inhibited protein synthesis (Machalin´ski et al. 1998),
Totipotent stem cell – blastomere
Pluripotent stem cells - embryonic node
(ectoderm, mesoderm, endoderm)
Multipotent stem cell - "tissue stem cell"
(e.g.: hematopoietic stem cells, HSCs)
Multipotent stem cell Progenitor cell
e.g.: (HSC) "reserve" (e.g.: HPC)
CFU-GEMM CFU- Lymph
Precursor of myeloid cell Precursor of lymphoid cell 
unipotent cell  unipotent cell  
(e.g.: erythrocyte, thrombocyte, macrophage)  (T and B lymphocytes, NK cells)
Fig. 1 Formation of
hematopoietic cell lines
(Dabrowski 1998a; Stojko
and Witek 2005; Yao et al.
2004)
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thereby it is slightly stained with fluorescent dyes,
such as Rhodamine 123, Hochest 33342, or Pyronin Y
(Dravid and Rao 2002; Machalin´ski et al. 1997;
Machalin´ski and Ratajczak 1997; Machalin´ski et al.
1998).
Activation of hematopoietic cells is combined with
its output from G0 phase to G1 phase, which is
characterized by increase of transcription and mRNA
accumulation. Cells derived from long-term cultures
have similar morphology: they are large and round,
with large and round nucleus, have a small amount of
cytoplasm, which is also characteristic for HPC
progenitor cells (Tian et al. 2005).
Surface markers’ expressing on cord blood
hematopoietic cells
For several years, the surface marker—CD34 anti-
gen, was only used to determine the hematopoietic
cells. Nevertheless, most cells with CD34 antigen
expression of bone marrow or umbilical cord blood,
have other antigenic determinants. The immunophe-
notype of stem cells/progenitors can be assessed
using:
• the cytometric analysis of the presence of CD34/
CD38 proteoglycan
• analysis of the marker of mature line (HLA-DR)
• analysis of c-kit tyrosine kinase receptor and their
respective labeling with the antibodies conjugated
to fluorochromes (Stojko and Witek 2005).
As it is mentioned above, a characteristic feature of
hematopoietic stem and progenitor cells is the pre-
sence of CD34 antigen. It is a transmembrane
glycoprotein of approximately 104–120 kDa, which
belongs to the adhesion molecules known as sialomu-
cines. It is composed of a protein core of 40 kDa
containing 6 to 9 N-binding sites of glycosylation and
more than 9 O-binding sites of glycosylation (Tarach
1999). The cytoplasmic part of CD34 antigen has two
sites for the phosphorylation of protein kinase C, and
one site for tyrosine phosphorylation. Therefore its
function is associated with the occurrence of trans-
membrane signalling (Tarach 1999). CD34 antigen is
involved in the regulation of hematopoietic stem cell’s
adhesion to the stroma (Gutierrez-Rodriguez et al.
2000; Kopec´-Szle˛zak and Podstawka 2001). The
increase in the expression of CD34 antigen, mainly
precedes cell differentiation. Over 10 years ago,
Gallacher et al. (2000) have isolated CD34- cells
form mouse bone marrow, which possessed the ability
to repopulate with 300 times higher efficiency than
CD34? cells. This so-called side population (SP) has
also been found in pigs, monkeys, and in bone marrow
and umbilical cord blood of people. After 3–5 weeks
in culture SP-cells become mostly CD34? cells.
Therefore there is a hypothesis of the presence of a
‘‘stem cell cycle’’, which implies the possibility of a
reversible phase transition form CD34- to CD34?
(Gallacher et al. 2000; Tarach 1999).
DNA testing has shown that cells having antigen
CD34?, being in S phase, or G2/M cell cycle, show
increased expression of the CD38? antigen, which
reflects their activation (Belvedere et al. 1999; Kopec´-
Szle˛zak and Podstawka 2001; Qian-Lin et al. 1995).
Cells expressing the CD34?CD38- antigens are
inhibited in the G0 phase. CD38? antigen determines
more diverse cells than those without this marker:
CD34?CD38- are more primitive than CD34?
CD38? (Summers et al. 2001; Tian et al. 2005).
Another antigen used to determine the degree of
maturity is CD90 antigen, also known as Thy-1. It
occurs on primitive cells or early progenitors, and its
lack is observed on late progenitors. Studies have shown
that the number of CD34?CD90? cells correlates
positively with the number of CD34?CD38- cells.
Co-expression of CD117 and CD135 antigens (with
tyrosine kinase receptor properties) is also used for the
determination of the maturity of early CD34? cells.
More than 60 % of the population of CD34? cells
shows co-expression of CD117 antigen, which is also
known as the c-kit receptor for the stem cell factor
(SCF) (Dabrowski 1998a; Ruzicka et al. 2004).
Primitive CD34? cells generally have low expression
of this antigen, in contrast to the progenitor cells, where
its higher expression is observed. 90 % of CD34? cord
blood cells show expression of CD135 antigen with
properties of tyrosine kinase, and 25 % of CD34? cells
show the CD95 antigen expression, which probably
acts as a regulator during early hematopoiesis (Kopec´-
Szle˛zak and Podstawka 2001). Antigen CD71 is the
transferrin receptor, which is situated on the surface of
hematopoietic cells. The primary lack of this antigen
on primitive cells and its later appearance on them,
suggests that these cells will be differentiated into the
line of CFU- E (the characteristic antigen pattern for
this line is CD34?CD45-CD71?) (Fasouliotis and
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Schenker 2000, Kopec´-Szle˛zak and Podstawka 2001).
At the very early stage of differentiation, co-expression
of CD45RO and CD45RB antigens exists, without
expression of the CD45RA antigen. This antigen is
characteristic of late progenitors, and suggests that
CFU-GM cell line will develop (Fasouliotis and
Schenker 2000; Kopec´-Szle˛zak and Podstawka 2001)
(immunophenotype CD34?CD45RA?CD71-).
On the CD34? cells there is also found the AC 133
antigen. It is a glycosylated protein with molecular
weight of 120 kDa. It does not show homology to any
of the previously described antigens present on
hematopoietic cells—the structure is unique among
other cell surface antigens. It has an extracellular
N-terminus, which is a 5-transmembrane domain and
the cytoplasmic C-end. This antigen appears to play
role of a growth factor receptor. The presence of the
five C-terminal tyrosine on it, indicates that this
protein is phosphorylated in response to attachment of
the ligand (Miraglia et al. 1997). AC133 expression is
shown mainly by CD34? Lin- cells, but there is also
evidences of the presence of this antigen in the
population of CD34-Lin- cells (Gallacher et al. 2000;
Grskovic et al. 2004).
To assess the proliferative potential of already
phenotypically identified hematopoietic cells—clono-
genic assays (e.g.: CFU-GM, CFU-M, BFU-E) and
culture assays (LTC-IC, Long Term Culture Initiating
Cell) are needed (37, 44). Grskovic et al. suggest that
colony forming cells (CFC) in ex vivo cultures are
derived from CD34? cells with low co-expression of
c-kit (CD117). Additionally, the presence of CD135
antigen has influence on the proliferative-differential
activity of these cells. Smogorzewska et al. have
noticed that CD34?CD38- cells were able to form
colonies (CFU) after 60 days of co-culture in the
presence of bone marrow stroma, unlike to
CD34?CD38? cells, which were not able to form
CFU in culture beyond 40 days.
Differences between cord blood, peripheral blood
and bone marrow
Differences in cell’s content and composition
Cord blood cells differ from their counterparts in the
peripheral blood or bone marrow, both in composition,
number, and properties (Marian´ska 1997; Qian-Lin
et al. 1995, Thierry et al. 1992; Zhou et al. 2001). Cells
in cord blood (with a CD34?CD38- phenotype)
which are found in the G0 phase have greater prolif-
erative response to cytokines and are less dependent on
stromal cells than the corresponding cells in the bone
marrow or peripheral blood (Kopec´-Szle˛zak and
Podstawka 2001; Smogorzewska et al. 1997; Zhou
et al. 2001). Studies of Gao et al. indicate that in the cord
blood there are hematopoietic precursors of stroma
(Gao et al. 2006). In the umbilical cord blood, HPP-
CFC cells (high proliferative potential colony forming
cell–cells with high proliferative potential, capable of
forming colonies) are also present in an amount
exceeding eight times their content in bone marrow
(Czajka et al. 1999; Marian´ska 1997, 2000; Stojko and
Witek 2005). Analysis of CFCs present in the human
umbilical cord blood shows that in 1 ml of blood there is
about 8,000 of BFU-E (i.e. 3 times more than in the
bone marrow or peripheral blood) between 13,000 and
24,000 of CFU-GM (i.e. 15 times higher concentration
than in the bone marrow or peripheral blood) and
between 1,000 and 10,000 of CFU-GEMM (Brunet de
la Grange et al. 2002; Fasouliotis and Schenker 2000).
In addition, cord blood contains a higher proportion of
more primitive hematopoietic cells than bone marrow
(Smogorzewska et al. 1997). The value of cord blood
cells expressing on their surface CD34 antigen is
approximately 0.02–1.43 %. This value is closed to the
percentage of CD34? cells found in the bone marrow
of adult (0.5–5 %) rather than in the peripheral blood
(\0.01 %) (Stolarek and Mys´liwski 2005). The number
of CD34 ?HLA-DR—cells, and CD34?CD38- cells
in the cord blood is higher than in the bone marrow (4 %
in the umbilical cord blood and 1 % in bone marrow)
(Stojko and Witek 2005).
On the CD34? cells of umbilical cord blood, there
is higher expression of CD44 proteoglycan and other
adhesion molecules of integrins group such as CD49d
or CD49f, but lower expression of CD11 and CD18
than in the same cells of the bone marrow or peripheral
blood (Kopec´-Szle˛zak and Podstawka 2001).
Cord blood cells are also characterized by long
telomere DNA in comparison to their analogues from
peripheral blood or bone marrow (Da˛browski 1998a;
Fasouliotis and Schenker 2000; Zhou et al. 2001).
Therefore cells form cord blood are capable for
hematopoiesis for a longer time—they generate more
divisions and generate a larger number of progeny
(daughter cells).
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Cord blood cells, which belong to the immune
system, also have many differences as compared with
the corresponding cells in the bone marrow or
peripheral blood (Je˛drasiak et al. 1999; Zeman et al.
1996). The immunoreactivity of effector cells, such as
lymphocytes and monocytes, and the total number of
B lymphocytes are relatively close; however, the
number of sub-populations of B cells is different. Half
of the population are immature cells with the pheno-
type CD19? CD5?. The total number of CD4? and
CD8? cells is smaller, but the ratio of CD4?/CD8? is
greater than in peripheral blood (Zeman et al. 1996).
Umbilical cord blood contains a characteristic T cell
population (with phenotype CD3-/CD8-), which is
the precursor of T cell line (Dabrowski 1998a). A large
number of studies indicate a lower percentage of NK
cells in cord blood and consequently a lower cytotoxic
activity as compared with the results obtained in adults
(Zeman et al. 1996). Low level of natural cytotoxicity
of umbilical cord blood cells is explained by ‘‘naive’’
feature of immune cells of umbilical cord blood and
probably is a characteristic value of the perinatal and
neonatal periods, which do not depend on exogenous
factors (Je˛drasiak et al. 1999; Kamin´ski et al. 1996;
Pietruszczuk et al. 1998). CD34? cells of cord blood
are also more resistant to Pyronin Y staining as
compared with the same fraction of bone marrow. It is
explained by the fact, that the CD34? cells in cord
blood, under childbirth stress condition, are constantly
stimulated by many cytokines, and therefore are less
sensitive to the possible toxic environmental sub-
stances (Machalin´ski et al. 1998).
The presence, in umbilical cord blood, of mesen-
chymal stem cells that are precursors of certain types
of cells (e.g.: bone, cartilage, fat or muscle) is no
longer a controversial issue (Stolarek and Mys´liwski
2005). Chang et al. showed that except for HSC,
umbilical cord blood, similarly to bone marrow,
contains mesenchymal stem cell (MPC—mesenchy-
mal stem cell/mesenchymal cell progenitor) (Chang
et al. 2006). Lee et al. have found that cord blood
contains more primitive multipotential population
MPC, which are able to differentiate into cells derived
from the three germ layers (Lee et al. 2005). Chang
et al. have noticed in cord blood two morphologically
distinct phenotypes of MPC: the first described as
lobar flattened fibroblast clones (F-MPC, about 93 %),
the second as a spindle—shaped fibroblast clones (SS-
MPC). In addition, researchers analyzed the surface
markers of these two phenotypes of MPC. Both types
were negative for antigen CD34, CD26, CD31, CD45
and HLA-DR. They showed, in turn, the expression of
cell surface antigens typical for mesenchymal pro-
genitors, such as: SH2, SH3 and SH4, adherent
molecules of CD29, CD44 and HLA antigens—A,
B, C. The only difference between these two types of
MPC is the CD90 antigen expression: spindle shape-
MPC exhibited high expression of the antigen, while
flattened-MPC showed no CD90 expression (Chang
et al. 2006).
Differences in cytokine’s composition
and production
Hematopoietic microenvironment is the place of
origin of cell’s proliferation, cell’s differentiation
and cell’s development. Fibroblasts, macrophages,
osteoblasts, endothelial cells, and T cells (Th1 and
Th2), which are present in this microenvironment,
produce growth factors. The effect of these growth
factors depends on the target cell, on the cytokine
concentration and on the presence of other cytokines
(Brunet de la Grange et al. 2002; Czajka et al. 1999;
Majka et al. 2001; Verhasselt et al. 1999; Yao et al.
2004; Zhou et al. 2001).
In vitro studies revealed that CD34? cord blood
cells have higher affinity to stromal cell derived factor
(SDF-1) than their counterparts in the bone marrow or
peripheral blood (Kopec´-Szle˛zak and Podstawka
2001; Ławicki et al. 2001). CD34? cells of cord
blood, in comparison with them, strongly react also on
Interleukin 3 (IL-3), IL-6 and SCF, which brings about
a considerably greater number of formed colonies
(Cicuttini et al. 1993; Dabrowski 1998b; Wagner et al.
1992).
Bogunia-Kubik has implicated that cord blood cells
produce less cytokines in comparison with corre-
sponding peripheral blood cells. The imbalance affects
both the quantity of synthesized protein, its bioactivity
and the number of cells producing cytokines. T cells,
NK cells and macrophages of cord blood, produce
small amounts of G-CSF, GM-CSF, IL-3, M-CSF,
TGF-b, IL-4, IL-2, IFN-c (Dabrowski 1998b, Gao
et al. 2006; Ławicki et al. 2001).
Limited cytokine synthesis by the cells of umbilical
cord blood can be the result of:
a. ‘‘naive’’ antigen feature (Bogunia-Kubik 2001)
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b. may be associated with decreased expression of
mRNA, which encode a gene for cytokine,
thereupon with less accumulation of cytokine’s
mRNA and its volatility (Bogunia-Kubik 2001)
c. reducing the production of cytokines, which may
also be due to differences in signal transduction
through the umbilical cord blood cells and
peripheral blood and/or immaturity of the signal
transduction mechanism in umbilical cord blood
cells. According to some researchers the low
response of umbilical cord blood cells is associ-
ated with a defect in the transmission of stimula-
tory signals through CD3 or with a defect in the
TCR’s signal transduction. In contrast, other
studies have shown, that decreased in vivo syn-
thesis of cytokines by ‘‘naive’’ T cells (phenotype
CD45RA?) from umbilical cord blood is not the
result of a defect within the cells but rather high
threshold of activation required by these cells
(Bogunia-Kubik 2001)
d. reduced production of cytokines, which may also
be associated with suppressor properties of serum
(Bogunia-Kubik 2001).
The role of certain cytokines in the culture
of umbilical cord blood cells
Each cell must dispose of the basic energy needs to
differentiate into the appropriate type. Under physio-
logical conditions, such situation is possible thanks to
the interaction between cells responsible for main-
taining of the homeostasis. In vitro conditions include
appropriate methods of cell’s culture and the need to
use certain media and grow factors. Since the begin-
ning of the use of umbilical cord blood as source of
hematopoietic stem cells, the development of tech-
niques for obtaining cord blood cells and of culture
methods have been reported. With using the appro-
priate ‘‘cocktail’’ of cytokines and specific media, it is
possible to grow the cultures of human erythroblasts,
megakaryoblasts and precursors of granulocyte–mac-
rophage line (Lawicki et al. 2001; Stolarek and
Mys´liwski 2005).
An important issue is not only the type of factors,
but also their concentration and sequence of admin-
istration. Stec et al. have found that providing (during
the first 3 days) so-called ‘‘early cytokines’’ (SCF, IL-
3, Flt3, Tpo) and a medium containing 4 % bovine
serum for the HSC, and next the transfer these cells to
medium containing 20 % bovine serum and growth
factors such as: M-CSF, Flt3, IL-3, SCF cause the
expansion of CD 14cells (Stec et al. 2003) (Table 1).
Growth factors, such as SCF, Flt3, IL-11, IL-3, IL-6,
GM-CSF are responsible for the proliferation of the
cells, while others, such as: M-CSF, G-CSF, Epo and
Tpo are responsible for differentiation and maturation of
cells. SCF, IL-3 and IL-6 are cytokines, which act in the
G0/G1 phase of the cell cycle, and by working together
induce mitosis (Grskovic et al. 2004) (Table 2).
Table 1 Antigens expressed on HSC (Belvedere et al. 1999;
Gutierrez-Rodriguez et al. 2000; Kopec´-Szle˛zak and Podst-
awka 2001; Qian-Lin et al. 1995; Summers et al. 2001; Tarach
1999; Tian et al. 2005)
Surface marker Occurrence
CD34 Stem cells, progenitor cells
CD38 Stem cells, early progenitor cells
CD90 Primitive cells, early progenitors
CD117 Progenitor cells
CD71 Precursor cells of CFU-E
CD45RA Late progenitors of CFU-GM
CD135 Stem cells, progenitor cells
AC133 Stem cells
Table 2 Differences between stem cells from different origins
(Brunet de la Grange et al. 2002; Czajka et al. 1999; Fasouliotis
and Schenker 2000; Kopec´-Szle˛zak and Podstawka 2001;
Marian´ska 1997, 2000; Stojko and Witek 2005; Stolarek and









BFU-E content 8,000/ml 2,500/ml
CFU-GM 13,000–24,000/ml 870–1,600/ml




4 % 1 %
Content of NK cells Lower Higher
Content of Th and Tc Lower Higher
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SCF
A stem cell factor (SCF)—is produced by bone
marrow stromal cells, T lymphocytes, hepatocytes
and fibroblasts. It reacts with the c-kit receptor, which
is built of the extracellular SCF binding site, the
transmembrane hydrophobic part and intracellular
part with the tyrosine kinase activity. This receptor
is present on the surface of bone marrow precursor
cells and certain leukemic lines, in a number from
2,500 to 30,000 per cell (Dabrowski 1998b) (Table 3).
Hematopoietic stem cell is the primary target for
SCF, however, this factor stimulates the differentia-
tion of HSCs only in a small percentage of cases. It is a
good co-stimulator of growth and acts synergistically
with other factors. SCF has influence on poorly
differentiated stem cells, especially on hematopoietic
cells, which are in early and intermediate stage of
growth. In vitro, SCF works only when other growth
factors are present in the medium (e.g.: IL-3, GM-
CSF, G-CSF, Epo). For instance, it was observed that
SCF interacts with EPO and stimulates therefore the
erythroblasts colony formation, with GM-CSF or IL-
3—it causes the formation of mixed colonies of early
progenitor cells, with G-CSF—it stimulates neutro-
philes colony formation (Dabrowski 1998b), and in
conjunction with IL-7—it stimulates the early stages
of B cell differentiation (Dabrowski 1998b; Ruzicka
et al. 2004) (Table 4).
Table 3 Ex vivo expansion of CD34? CD38- cord blood
cells due to implemented cytokines (Czajka et al. 1999; Dravid
and Rao 2002; Jinquan et al. 2001; Kucia and Drukała 2002;




Cytokines sets Expansion of LTC-IC
CD34?CD38- SCF, Flt3, IL-3, IL-
6, IL-11, LIF,
HSC division
















CD34?CD38- IL-3, IL-6, IL-2,
IL-9, IL-1, IL-7
Thymocytes




CD34?CD38- IL-3, IL-6, IL-11,
IL-9, Epo, LIF
Erythrocytes (CFU-E)
CD34?CD38- IL-3, IL-10, GM-



















Table 4 Role of cytokines (Chen and Wang 2014; Dabrowski
1998b; Je˛drzejczak 1997; Jinquan et al. 2001; Li et al. 2010;
Lawicki et al. 2001; Ruzicka et al. 2004)
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IL-3
Interleukin 3 is known as multipotential colony
stimulating factor (multi-CSF), or mast cell growth
factor (MC-GF). It is a glycoprotein with a molecular
weight of 14–30 kDa. It is produced by activated T
cells, NK cells, mast cells and some leukemia cell
lines. IL-3 exerts its effect through the current cell
receptor for interleukin 3 (IL3-R or CD123). IL-3
receptor is composed of two chains a and b, and shows
a strong similarity to the GM-CSF receptor. IL-3
stimulates cell proliferation and differentiation of
granulocyte–macrophages, erythrocytes, megakaryo-
cytes, eosinophils and mast’s cell progenitors. The
total number of CD123 on the surface of the progen-
itors mentioned above is about 200–13,000 per cell
and decreases with their maturation, which indicates
that IL-3 is a more proliferative cytokine than
cytokines, which stimulate the functions of mature
cells (Je˛drzejczak 1997).
IL-3 acts synergistically with other growth factors,
mainly with GM-CSF, G-CSF, IL-6 and IL-11. This is
confirmed by in vitro studies, in which the addition of
IL-3 with GM-CSF to the cell culture results in a larger
number of granulocyte–macrophage colony than with
sole GM-CSF (Lawicki et al. 2001). In combination
with other cytokines, which act in the early stages of
hematopoiesis, such as SCF, IL-1 or IL-6, it supports
the formation of colonies and their expansion in
culture (Ruzicka et al. 2004).
IL-6
Interleukin 6 is a so-called inflammatory cytokine. It is
produced by fibroblasts, activated T cells, activated
monocytes, macrophages and endothelial cells. IL-6
increases the expression of most of cell surface
antigens, which are characteristic for myeloid lines.
IL-6 is a potent co-factor for the survival and
proliferation of primitive progenitors and it acts on
the cell by the interaction of two receptors: IL-6R and
gp130-R. The stimulation with SCF, IL-6 and Epo
induces rapid proliferation of selective stimulation of
erythropoiesis. It has been shown that the addition of
IL-6 to the medium without serum supplementation in
a short-term culture had beneficial effects on HSC
expansion of umbilical cord blood and also prevented
the negative effect caused by IL-3 in the long-term
culture (Ruzicka et al. 2004).
GM-CSF
Granulocyte-macrophage colony stimulating factor
(GM-CSF) is a glycoprotein with a mass of
14–35 kDa. It is produced mainly by activated T
cells, endothelial cells, fibroblasts and mast cells. GM-
CSF receptor belongs to the hematopoiethines family
receptors without internal tyrosine kinase activity
properties (Je˛drzejczak 1997; Jinquan et al. 2001).
Large quantity of this receptor is found on the cells
of the granulocyte line, but this amount changes
during maturation. In vitro, GM-CSF stimulates the
formation of granulocytes and monocytes colony.
Recent studies have shown that GM-CSF induces on
CD34? cells the expression of CXCR3 (it is a receptor
present on activated T cells and memory cells), and
therefore has influence on the differentiation of
CD34? cells into appropriate type of precursor and
their later maturation (Jinquan et al. 2001). In vivo,
GM-CSF reduces the time of transition from resting
phase to meiosis and S-phase duration, and affects
lymphoid progenitor cells causing their proliferation
and maturation (Lawicki et al. 2001; Tian et al. 2005).
IL-9
IL-9 was first identified as a mouse T cell growth
factor but with time it has also been demonstrated to
modulate B cell maturation, IgE production and
promote proliferation and differentiation of mast cells
and hematopoietic progenitors. IL-9 is proposed to be
a candidate gene for asthma (Chen and Wang 2014;
Townsend et al. 2000) and with IL-3 it acts synergis-
tically for maximal proliferation of mast cells. There-
fore, IL-9 is described as a T cell derived cytokine with
pleiotropic activities on various cell types. The action
of IL-9 on thymocytes in vitro is interesting in view of
the development of thymic lymphomas. In IL-9
transgenic mice it has been observed that IL-9 is a
major anti-apoptotic factor for thymic lymphomas
(Damera et al. 2006; De Smedt et al. 2000).
The functions of IL-9 are mediated by the IL-9
receptor (IL-9R), which is a member of the superfam-
ily of hematopoietic receptors. The human IL-9R gene
contains 11 exons and encodes a 522 amino acid
protein. IL-9R is expressed in T-cell lines and effector
T cells, but not in naive T cells. Among the Th cell
subsets, IL-9R exhibits its highest expression in Th2
and Th17 cells (Chen and Wang 2014; Li et al. 2010).
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